Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,716 | -37,034 | -13,167 | -8,196 | N/A |
| Depreciation Amortization | 654 | 317 | 761 | 1,671 | N/A |
| Accounts receivable | N/A | N/A | N/A | -4 | N/A |
| Other Working Capital | 2,941 | 3,224 | 1,930 | -808 | N/A |
| Other Operating Activity | 4,714 | 6,010 | -856 | 126 | 0 |
| Operating Cash Flow | $-52,407 | $-27,483 | $-11,332 | $-7,211 | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 1,366 | N/A |
| PPE Investments | -414 | -229 | -19 | N/A | N/A |
| Purchase Of Investment | -77,175 | -77,708 | -13,396 | N/A | N/A |
| Sale Of Investment | 63,901 | 12,585 | 1,990 | N/A | N/A |
| Investing Cash Flow | $-13,688 | $-65,352 | $-11,425 | $1,366 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -7 | -3 | N/A | N/A | N/A |
| Common Stock Issued | 83,100 | 104,328 | 5 | N/A | N/A |
| Common Stock Repurchased | N/A | -162 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 237 | 42,326 | 2,475 | 0 |
| Financing Cash Flow | $83,093 | $104,400 | $42,331 | $2,475 | $N/A |
| Beginning Cash Position | 32,780 | 21,215 | 1,641 | 5,011 | N/A |
| End Cash Position | 49,778 | 32,780 | 21,215 | 1,641 | N/A |
| Net Cash Flow | $16,998 | $11,565 | $19,574 | $-3,370 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -52,407 | -27,483 | -11,332 | -7,211 | N/A |
| Capital Expenditure | -414 | -229 | -19 | N/A | N/A |
| Free Cash Flow | -52,821 | -27,712 | -11,351 | -7,211 | 0 |